Ep 82: Best of ASCO: 2026

from Melanoma Matters · host Melanoma Matters Pod

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.Studies discussed include:OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy

Episode metadata supplied by the publisher feed · Published Jun 13, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep 82: Best of ASCO: 2026

0:00 1:04:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Melanoma Matters?

This episode is 1 hour and 4 minutes long.

When was this Melanoma Matters episode published?

This episode was published on June 13, 2026.

Can I download this Melanoma Matters episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!